Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
OBJECTIVE
Long-term acid suppression reduces the risk of progression to esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE). Given recent reports about the harmful effects of using chronic proton pump inhibitors (PPI) there is renewed interest in alternative methods of acid suppression. Hence, we studied the effect of H2 receptor antagonists (H2 RA) on the risk of progression to neoplasia in our BE cohort.


METHODS
This is a retrospective analysis of prospectively collected data of patients in our BE registry from 2002 to 2015. Patients' characteristics, endoscopic findings, such as the length of BE, hiatal hernia size and histological findings and patients' use of medications such as PPI, aspirin, H2 RA, metformin and antihyperlipidemic agents were studied.


RESULTS
The cohort consisted of 1466 patients with a mean age of 61 ± 13 years. The patients had a predominance of male sex (76.7% [1118/1457]) and Caucasian race (96.6% [1209/1252]). After excluding prevalent high-grade dysplasia (HGD) or EAC, 1025 patients had a median follow up of 43.6 months during which 57 patients progressed to HGD or EAC. PPI use (56% in progressors vs 69% in non-progressors; P = 0.007) but not H2 RA use (12% progressors vs 19% in non-progressors P = 0.162) was associated with lower risk of neoplastic progression. On multivariate analysis, there was no synergistic effect of addition of H2 RA to PPI on risk of neoplastic progression to HGD or EAC (relative risk 0.33; confidence intervals 0.05-2.29, P = 0.262).


CONCLUSION
H2 RA do not seem to have a chemopreventive role in patients with BE.
['Thota|Prashanthi N|PN|', 'Hajifathalian|Kaveh|K|', 'Benjamin|Tanmayee|T|', 'Runkana|Ashok|A|', 'Lopez|Rocio|R|', 'Sanaka|Madhusudhan R|MR|']
D000230:Adenocarcinoma D000328:Adult D000368:Aged D016588:Anticarcinogenic Agents D001471:Barrett Esophagus D018450:Disease Progression D004938:Esophageal Neoplasms D004945:Esophagoscopy D005260:Female D005500:Follow-Up Studies D006635:Histamine H2 Antagonists D006801:Humans D008297:Male D008875:Middle Aged D009820:Ohio D011230:Precancerous Conditions D015995:Prevalence D054328:Proton Pump Inhibitors D012189:Retrospective Studies D018570:Risk Assessment
histamine receptor antagonist progression Barrett's esophagus neoplasia dysplasia